Publication
Article
CE: Use of Oncology Supportive Care Biosimilars During COVID-19: Clinical Strategies for Pharmacists
Cancer medications contribute substantially to the cost of health care in the United States, with 8 of the 10 most expensive drugs indicated for the treatment of cancer
THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM COHERUS BIOSCIENCES, INC.
EDUCATIONAL OBJECTIVES
At the completion of this activity, the participant will be able to:
• Examine current oncology supportive care biosimilars and the place in clinical practice for granulocyte colony-stimulating factors
• Investigate current challenges surrounding supportive care biosimilars in clinical practice during the COVID-19 pandemic
• Identify safe practices and strategies for appropriate use of supportive care biosimilars in clinical practice during the COVID-19 pandemic
• Explain economic considerations of supportive care agents
FACULTY
Julianna Merten, PharmD, BCPS, BCOP
Ambulatory Care Pharmacist
Assistant Professor of Pharmacy, College of Medicine, Mayo Clinic, Rochester, Minnesota
Chimeric Medical Communications, LLC, Saint Ansgar, Iowa
TARGET AUDIENCE: Oncology, health-system, managed care, specialty, and retail pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: July 15, 2020
EXPIRATION DATE: July 15, 2021
ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours
FEE: This lesson is offered for free at www.pharmacytimes.org.
